Structure Therapeutics (NASDAQ:GPCR) Trading Up 5.6% – Still a Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares rose 5.6% on Thursday . The stock traded as high as $29.87 and last traded at $29.84. Approximately 85,014 shares were traded during trading, a decline of 89% from the average daily volume of 797,037 shares. The stock had previously closed at $28.25.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. JMP Securities reiterated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Finally, Morgan Stanley started coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $86.50.

Structure Therapeutics Trading Up 7.2 %

The business has a fifty day moving average of $34.78 and a 200-day moving average of $38.19. The company has a market cap of $1.73 billion, a PE ratio of -40.93 and a beta of -3.41.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently bought and sold shares of GPCR. Sandia Investment Management LP bought a new position in Structure Therapeutics in the 2nd quarter worth about $39,000. Assetmark Inc. raised its position in Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after acquiring an additional 719 shares during the period. Quarry LP bought a new stake in shares of Structure Therapeutics during the 2nd quarter valued at $79,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares during the period. Finally, Dearborn Partners LLC purchased a new position in Structure Therapeutics during the third quarter valued at $202,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.